Skip to main content

Table 1 Demographic and clinical characteristics of patients with RA and HC

From: Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis

  RA (10) HC (10)
Age at the time of biopsy (median years, range) 56 (45–61) 58 (45–63)
Gender (n, % of female) 9 (90%) 8 (80%)
Disease duration (median years, range) 3 (1–5) NA
ACPA positivity (n, %) 10 (100%) NA
RF status (n, %) 10 (100%) NA
DAS28 (median, range) 5.1 (4.8–5.9) NA
Low dosage of steroids (n, %) 8 (80%) NA
Methotrexate (n, %) 10 (100%) NA
  1. RA rheumatoid arthritis, HC healthy controls, DAS28 Disease Activity Score on 28 joints, ACPA anti citrullinated peptide antibody, RF rheumatoid factor, NA not applicable